Short- and Long-Term Risk Stratification in Acute Coronary Syndromes

[Epidemiology of acute coronary syndrome in France]

Coronary artery disease remains a major cause of death in France. Epidemiology of acute coronary syndromes (ACS) encompasses the study of trends of mortality, incidence and case fatality. Methodology includes data from populational and hospital registries of ACS. Incidence and mortality rates of ACS are significantly higher in the North than in the South of France. Significant improvement of ACS mortality and hospital case fatality were registered from 1997 to 2002. However, a slow down in ACS incidence rates was shown during the same period and particularly in the South of France. Sudden death continues to be a major health concern due to problems of prevention. Pre-hospital management is also a major source of health inequalities and this merits further analysis of those disparities. Recent data have shown large improvement in acute coronary care but the relatively high rates of ACS incidence stress the need to promote primary prevention and the screening of minor atherosclerosis lesions.

New biochemical markers: from bench to bedside

BACKGROUND

Evaluation of patients presenting to hospital with chest pain or other signs or symptoms suggesting acute coronary syndrome (ACS) is problematic, time-consuming and sometimes expensive, even if new biochemical markers, such as troponins, have improved the ability to detect cardiac injury. However, patients with normal troponin values are not necessarily risk-free for major cardiac events.

METHODS

Recent investigations indicate that the overall patient risk may be assessed earlier than before, thanks to new knowledge acquired concerning the pathobiology of atherosclerosis and molecular events involved in the progression of disease, thus allowing the development of new biochemical markers. Some selected markers are released during the different phases of development of cardiovascular disease and may be useful for the diagnosis of patients with cardiovascular disease. In particular, the identification of emerging markers that provide relevant information on the inflammatory process, and the development of biomarkers whose circulating concentrations suggest the status of plaque instability and rupture, seems to be of particular value in prognosis and risk stratification. The overall expectations for a cardiovascular biochemical marker are not only its biological plausibility but also the availability at a reasonable cost of rapid, high quality assays, and their correct interpretation by clinicians using optimal cut-offs.

CONCLUSION

The crossing from bench to bedside for each new marker discovered, must be associated with concurrent advances in the characterization of analytical features and the development of routine assay, in the assessment of analytical performance and in interpretative reporting of test results as well as in the training of physicians to use the array of biomarkers available appropriately and to interpret them correctly. This approach calls for the coordinated support of clinicians, technology experts, statisticians and the industry so that new biochemical developments can be of optimal value.